Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.0052W HIGH $30.74
Volume
187.34 K
Value Traded
60.79 M
Short % Float
8.71%
-5.4%Week
+9.83%1 Month
+27.35%3 Month
+109.7%6 Month
-61.96%5 Year
-64.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.26 B
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
3.85 B
Total Shares
159.62 M
Float Shares
154.87 M
Insiders
2.96%
Institutions
97.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ADPT Catalyst Timeline
Dated clinical, regulatory and corporate events for Adaptive Biotechnologies Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adaptive Biotechnologies Corporation
273Total events
3Upcoming
27Tier-1 (high impact)
2019 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Timing GuidanceclonoSEQApprovedPresentation
New IMS/IMWG consensus definition of cure for multiple myeloma presented at IMS 23rd Annual Meeting
multiple myelomasource ↗
▲Timing GuidanceclonoSEQApprovedPresentation
NCCN Guidelines updated to include dedicated Principles of MRD Testing page (MYEL-E) and expanded MRD recommendations naming clonoSEQ
Multiple Myelomasource ↗
▲Timing GuidanceclonoSEQApprovedPresentation
NCCN Guidelines update supporting highly sensitive MRD assessment in myeloma care
multiple myelomasource ↗
◆Pipeline PrioritizationCorporate
Announced plans to separate MRD and Immune Medicine businesses
▼Debt Royalty FinancingCorporate
Completed $345 million zero-coupon convertible senior notes offering
▼Equity OfferingCorporate
Announced proposed offering of $250M convertible senior notes due 2031
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference Presentation
◆Oral PresentationclonoSEQApprovedPresentation
MRD-guided therapy duration/discontinuation data from BOVen-∆MRD400 presented at ASCO/EHA 2026
chronic lymphocytic leukemiasource ↗
▲Full ResultsclonoSEQApprovedClinical Data
Final analysis from CEPHEUS trial showing higher rates of sustained MRD negativity
multiple myelomasource ↗
◆Oral PresentationPresentation
Craig-Hallum 23rd Annual Institutional Investor Conference 1x1 Meetings
▲Milestone PaymentclonoSEQApprovedCorporate
First U.S. primary endpoint milestone revenue recognized ($9.0M)
MRDsource ↗
▲Partnership / LicenseCorporate
Adaptive Biotechnologies announces data licensing agreement with Pfizer for TCR-antigen datasets
multiple immunology applicationssource ↗
◆Oral PresentationPresentation
Jefferies Fireside Chat on MRD with clonoSEQ assay technology
Minimal Residual Disease in Hematology/Oncologysource ↗
◆Oral PresentationclonoSEQApprovedPresentation
36 oral presentations featuring clonoSEQ MRD data at ASH 2025
multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, other blood cancerssource ↗
◆Poster PresentationclonoSEQApprovedPresentation
Poster presentations featuring clonoSEQ MRD data at ASH 2025
multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, other blood cancerssource ↗
▲Quarterly UpdateclonoSEQApprovedCorporate
MRD business achieved profitability and cash flow positivity
minimal residual disease (MRD)source ↗
◆Oral PresentationPresentation
Adaptive Biotechnologies to participate in Morgan Stanley 23rd Annual Global Healthcare Conference fireside chat
▲Partnership / LicenseclonoSEQApprovedCorporate
Integration of clonoSEQ MRD testing into OncoEMR EMR platform
lymphoid malignanciessource ↗
▲Quarterly UpdateclonoSEQApprovedCorporate
clonoSEQ test volume grew 37% to 25,321 tests in Q2 2025 vs Q2 2024
minimal residual disease (MRD)source ↗
▲Quarterly UpdateCorporate
MRD business achieved profitability with Adjusted EBITDA of $1.9M in Q2 2025
▲Partnership / LicenseclonoSEQApprovedCorporate
Launched integration of clonoSEQ into Flatiron's OncoEMR
minimal residual disease (MRD)source ↗
●Manufacturing MilestoneclonoSEQApprovedCMC / Inspection
Implemented NovaSeq X Plus for clonoSEQ clinical sequencing
minimal residual disease (MRD)source ↗
▲Milestone PaymentCorporate
Recognized $5.5M in MRD pharma regulatory milestone revenue in Q2 2025
◆Oral PresentationclonoSEQApprovedPresentation
clonoSEQ data presentations in DLBCL anticipated at iCML
Diffuse Large B-Cell Lymphomasource ↗
◆Oral PresentationclonoSEQApprovedPresentation
Oral Presentation S112: Safety and efficacy of single-agent subcutaneous blinatumomab in adults with R/R B-ALL: phase 1/2 dose expansion
B-Cell Acute Lymphoblastic Leukemiasource ↗
◆Poster PresentationclonoSEQApprovedPresentation
Poster Presentation PS1568: Using MRD status to guide venetoclax treatment duration in CLL: interim results from VENETOSTOP
Chronic Lymphocytic Leukemiasource ↗
◆Oral PresentationclonoSEQApprovedPresentation
Oral Presentation S201: Phase 2 registrational study of anitocabtagene autoleucel for RRMM: updated results from IMMAGINE-1
Multiple Myelomasource ↗
◆Oral PresentationclonoSEQApprovedPresentation
Oral Presentation S117: Safety and efficacy of AZD0486 in adolescent and adult patients with R/R B-ALL: early results from SYRUS
B-Cell Acute Lymphoblastic Leukemiasource ↗
◆Poster PresentationclonoSEQApprovedPresentation
Poster Presentation PF372: Donor-derived allogeneic CD19/CD22-CAR T cells with myeloablative graft-engineered Allo-HCT for high-risk B-ALL
B-Cell Acute Lymphoblastic Leukemiasource ↗
◆Oral PresentationPresentation
Adaptive Biotechnologies to participate in Goldman Sachs 46th Annual Global Healthcare Conference fireside chat
◆Oral PresentationclonoSEQApprovedPresentation
Oral Presentation 7502: Sustained MRD negativity in NDMM treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (IsKia trial)
Multiple Myelomasource ↗
◆Oral PresentationclonoSEQApprovedPresentation
Oral Presentation 7515: MRD negativity in RRMM treated with belantamab mafodotin plus pomalidomide and dexamethasone vs PVd: DREAMM-8
Multiple Myelomasource ↗
◆Oral PresentationclonoSEQApprovedPresentation
Poster Presentation 6540: Initial results from a phase II study of DA-EPOCH ± rituximab + tafasitamab for adults with ND Ph- B-ALL
B-Cell Acute Lymphoblastic Leukemiasource ↗
◆Poster PresentationclonoSEQApprovedPresentation
Poster Presentation 7529: DVRd vs VRd in TIE/TD NDMM: CEPHEUS cytogenetic subgroup analysis
Multiple Myelomasource ↗
▲Quarterly UpdateclonoSEQApprovedCorporate
Expanded Medicare coverage for recurrence monitoring in mantle cell lymphoma
mantle cell lymphomasource ↗
▲Other Regulator MilestoneclonoSEQApprovedEx-US Regulatory
Expanded Medicare coverage for clonoSEQ surveillance testing in MCL
mantle cell lymphoma (MCL)source ↗
▲Other Regulator MilestoneclonoSEQApprovedEx-US Regulatory
New York State CLEP approval for enhanced clonoSEQ ctDNA assay in DLBCL
diffuse large B-cell lymphomasource ↗
Past FDA Catalysts and PDUFA Decisions
How ADPT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-05-30 | clonoSEQ® | Phase 2/3 data readout | Phase 2/3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ADPT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| clonoSEQ | B-cell acute lymphoblastic leukemia (B-ALL) | Phase 2 | 2025-12-08 | 51 patients who were NGS MRD negative and received a non-TBI regimenRead More | Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RUBINSTEIN JULIEOfficer (President and COO) | Option | 11,881 389,683 held | $12.14 | 10/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADPT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.4 % | 26.11 M | 1.22 M | 698.25% ( 1.06 M) |
ADPT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADPT ranks across every disease it competes in
Competitive Position is a premium feature
See how ADPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADPT News
ADPTAdaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Adaptive Biotechnologies highlighted a new consensus definition of cure for multiple myeloma during the International Myeloma Society meeting. This definition emphasizes sustained measurable residual disease (MRD) negativity as central to determining a cure. Patients may be considered cured after five years of complete remission, contingent on specific MRD testing criteria. The clonoSEQ test is pivotal in this assessment.
Read more →ADPTAdaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
Adaptive Biotechnologies announced significant updates to the NCCN Guidelines for Multiple Myeloma, emphasizing the importance of minimal residual disease (MRD) assessment. The guidelines now include a dedicated page for MRD testing, with clonoSEQ recognized as the only FDA-cleared assay. These updates aim to improve patient care by providing clearer recommendations for MRD testing and its role in treatment decisions.
Read more →ADPTAdaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Adaptive Biotechnologies Corporation will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York. The company's management is set to engage in a fireside chat on September 15, 2026. This event provides an opportunity for Adaptive to present its advancements in immune medicine and connect with investors.
Read more →ADPT▲ +7.2%on this news
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Adaptive Biotechnologies reported strong financial results for Q2 2026, with total revenue of $71.6 million, marking a 22% increase from the previous year. The company's MRD business saw significant growth, contributing 92% of total revenue. However, the Immune Medicine segment experienced a notable decline in revenue. The company also announced plans to separate its MRD and Immune Medicine businesses to enhance long-term value.
Read more →ADPTAdaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
Adaptive Biotechnologies Corporation will release its second quarter 2026 financial results on July 29, 2026, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results. The webcast will be available live and archived for later access, showcasing the company's commitment to investor relations.
Read more →ADPTImviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
Imviva Biotech has received FDA Investigational Device Exemption (IDE) authorization for its clonoSEQ® assay, which will be utilized in the TENACITY-01 clinical trial. This assay is designed for highly sensitive next-generation sequencing-based minimal residual disease (MRD) testing, focusing on patients with T-cell malignancies. The trial aims to enhance the identification of eligible patients and accurately assess their treatment responses.
Read more →ADPTAdaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Adaptive Biotechnologies Corporation has announced the pricing of an upsized $300 million offering of convertible senior notes due in 2031. The proceeds will be utilized to repay existing agreements, repurchase shares, and for general corporate purposes. The offering is set to close on June 22, 2026, with a conversion rate of 41.48 shares per $1,000 principal amount.
Read more →ADPTAdaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
Adaptive Biotechnologies plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to enhance growth and value creation. The MRD segment has reached profitability and expanded its clinical utility, while Immune Medicine is advancing its discovery capabilities. The company aims to finalize its separation strategy by the end of 2026.
Read more →ADPTAdaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
Adaptive Biotechnologies Corporation has announced a proposed offering of $250 million in convertible senior notes due 2031. The proceeds will be used to repay an existing purchase agreement, repurchase common stock, and support corporate initiatives in the Minimal Residual Disease (MRD) sector. The offering is subject to market conditions and includes an option for initial purchasers to buy additional notes.
Read more →ADPTAt ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Adaptive Biotechnologies announced that its clonoSEQ MRD testing will feature prominently at the ASCO and EHA conferences. The data presented highlights clonoSEQ's pivotal role in assessing treatment responses and guiding therapy decisions in hematologic malignancies. The technology is increasingly recognized as essential for modern oncology care, with significant implications for patient management.
Read more →ADPTAdaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has announced its participation in upcoming investor conferences, including the Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis and the William Blair 46th Annual Growth Stock Conference in Chicago. At these events, the company aims to engage with investors and showcase its advancements in leveraging the adaptive immune system for clinical applications. The presentation at the William Blair conference is scheduled for June 3rd, with a live and archived webcast available on the company's website.
Read more →ADPTAdaptive Biotechnologies Reports First Quarter 2026 Financial Results
Adaptive Biotechnologies reported a strong financial performance for Q1 2026, with revenues reaching $70.9 million, a 35% increase from the previous year. The Minimal Residual Disease (MRD) segment was a significant contributor, growing 53%. However, the company also reported a net loss of $20 million and a decline in Immune Medicine revenue by 57%. The company has raised its full-year MRD revenue guidance to between $260 million and $270 million.
Read more →ADPTAdaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
Adaptive Biotechnologies Corporation will announce its financial results for the first quarter of 2026 on May 5, 2026, after market close. A conference call will follow, allowing management to discuss the results. The company specializes in leveraging the adaptive immune system for disease diagnosis and treatment.
Read more →ADPTAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
Adaptive Biotechnologies reported strong financial results for Q4 and full year 2025, achieving a 51% revenue increase in Q4 and a 55% increase for the year. The company reached profitability in its Minimal Residual Disease (MRD) business and expects continued growth in 2026. However, it also reported a net loss of $13.6 million for Q4 2025, despite significant revenue growth.
Read more →ADPTAdaptive Biotechnologies to Participate in Upcoming Investor Conferences - January 27, 2026
Adaptive Biotechnologies Corporation announced its participation in upcoming investor conferences. The company focuses on leveraging the adaptive immune system for clinical products aimed at diagnosing and treating diseases. Interested investors can access live and archived webcasts on the company's website. Adaptive continues to develop its proprietary immune medicine platform.
Read more →ADPTAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
Adaptive Biotechnologies Corporation will announce its financial results for Q4 and the full year 2025 on February 5, 2026. The announcement includes a conference call that will be webcasted, allowing investors to access the information live. The company emphasizes its commitment to leveraging the adaptive immune system for disease diagnosis and treatment.
Read more →ADPT▲ +15.9%on this news
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
Adaptive Biotechnologies announced preliminary results for the fourth quarter and full year ended December 31, 2025, reporting a 46% growth in Minimal Residual Disease (MRD) revenue driven by clonoSEQ testing volume. CEO Chad Robins highlighted the strong performance and anticipated continued momentum into 2026, focusing on MRD testing leadership and profitability. However, the results are preliminary and still subject to audit, indicating potential changes in final figures. The company's complete financial results will be released during an earnings call in February 2026.
Read more →ADPTAdaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Scheduled for January 12, 2026, the presentation will showcase their developments in utilizing the adaptive immune system for disease diagnosis and treatment. Interested individuals can access a live and archived webcast of the presentation via the company's website. This participation signifies the company's commitment to advancing its clinical products and engaging with industry stakeholders.
Read more →ADPTAdaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
Adaptive Biotechnologies has entered into two licensing agreements with Pfizer to utilize its T-cell receptor (TCR) discovery platform. The first agreement focuses on identifying disease-specific TCRs in rheumatoid arthritis, while the second allows Pfizer access to Adaptive's TCR-antigen datasets for broader immunology research. These collaborations could lead to significant advancements in therapeutic development.
Read more →About Adaptive Biotechnologies Corporation
Headquarters1165 EASTLAKE AVE E, SEATTLE, WA, 98109
Founded2009
BIOPHARMAWATCH ELITE PLUS
Trade the next ADPT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime